|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. Ca Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hennessy BT, Coleman RL and Markman M:
Ovarian cancer. Lancet. 374:13712009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cai H and Xu Y: The role of LPA and YAP
signaling in long-term migration of human ovarian cancer cells.
Cell Commun Signal. 11:312013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hall CA, Wang R, Miao J, Oliva E, Shen X,
Wheeler T, Hilsenbeck SG, Orsulic S and Goode S: Hippo pathway
effector yap is an ovarian cancer oncogene. Cancer Res.
70:8517–8525. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arend RC, Londoño-Joshi AI, Straughn JM Jr
and Buchsbaum DJ: The Wnt/β-catenin pathway in ovarian cancer: A
review. Gynecol Oncol. 131:772–779. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takebe N, Harris PJ, Warren RQ and Ivy SP:
Targeting cancer stem cells by inhibiting wnt, notch, and hedgehog
pathways. Nat Rev Clin Oncol. 8:97–106. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park JT, Li M, Nakayama K, Mao TL,
Davidson B, Zhang Z, Kurman RJ, Eberhart CG, Shih IeM and Wang TL:
Notch3 gene amplification in ovarian cancer. Cancer Res.
66:6312–6318. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rose SL, Kunnimalaiyaan M, Drenzek J and
Seiler N: Notch 1 signaling is active in ovarian cancer. Gynecol
Oncol. 117:130–133. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Halder G and Johnson RL: Hippo signaling:
Growth control and beyond. Development. 138:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu FX and Guan KL: The hippo pathway:
Regulators and regulations. Genes Dev. 27:355–371. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Santucci M, Vignudelli T, Ferrari S, Mor
M, Scalvini L, Bolognesi ML, Uliassi E and Costi MP: The hippo
pathway and YAP/TAZ-TEAD protein-protein interaction as targets for
regenerative medicine and cancer treatment. J Med Chem.
58:4857–4873. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zaidi SK, Sullivan AJ, Medina R, Ito Y,
van Wijnen AJ, Stein JL, Lian JB and Stein GS: Tyrosine
phosphorylation controls Runx2-mediated subnuclear targeting of YAP
to repress transcription. EMBO J. 23:790–799. 2014. View Article : Google Scholar
|
|
13
|
Barry ER, Morikawa T, Butler BL, Shrestha
K, de la Rosa R, Yan KS, Fuchs CS, Magness ST, Smits R, Ogino S, et
al: Restriction of intestinal stem cell expansion and the
regenerative response by YAP. Nature. 493:106–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cai J, Zhang N, Zheng Y, de Wilde RF,
Maitra A and Pan D: The Hippo signaling pathway restricts the
oncogenic potential of an intestinal regeneration program. Genes
Dev. 24:2383–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hong W and Guan KL: The YAP and TAZ
transcription co-activators: Key downstream effectors of the
mammalian Hippo pathway. Semin Cell Dev Biol. 23:785–793. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Escoll M, Gargini R, Cuadrado A, Anton IM
and Wandosell F: Mutant p53 oncogenic functions in cancer stem
cells are regulated by WIP through YAP/TAZ. Oncogene. 36:3515–3527.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ferrarelli LK: Actin against BRAF
inhibitors. 9:ec51–ec. 2016.
|
|
18
|
Gayani DM, Kang CH, Hyun CY and Gi-Young
K: Mangiferin inhibits tumor necrosis factor-α-induced matrix
metalloproteinase-9 expression and cellular invasion by suppressing
nuclear factor-κB activity. BMB Rep. 48:559–564. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pan LL, Wang AY, Huang YQ, Luo Y and Ling
M: Mangiferin induces apoptosis by regulating Bcl-2 and Bax
expression in the CNE2 nasopharyngeal carcinoma cell line. Asian
Pac J Cancer Prev. 15:7065–7068. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li H, Huang J, Yang B, Xiang T, Yin X,
Peng W, Cheng W, Wan J, Luo F, Li H and Ren G: Mangiferin exerts
antitumor activity in breast cancer cells by regulating matrix
metalloproteinases, epithelial to mesenchymal transition, and
β-catenin signaling pathway. Toxicol Appl Pharmacol. 272:180–190.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Louisa M, Soediro TM and Suyatna FD: In
vitro modulation of P-glycoprotein, MRP-1 and BCRP expression by
mangiferin in doxorubicin-treated MCF-7 cells. Asian Pac J Cancer
Prev. 15:1639–1642. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rajendran P, Rengarajan T, Nishigaki I,
Ekambaram G and Sakthisekaran D: Potent chemopreventive effect of
mangiferin on lung carcinogenesis in experimental Swiss albino
mice. J Cancer Res Ther. 10:1033–1039. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shi W, Deng J, Tong R, Yang Y, He X, Lv J,
Wang H, Deng S, Qi P, Zhang D and Wang Y: Molecular mechanisms
underlying mangiferin-induced apoptosis and cell cycle arrest in
A549 human lung carcinoma cells. Mol Med Rep. 13:3423–3432. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zou B, Wang H, Liu Y, Qi P, Lei T, Sun M
and Wang Y: Mangiferin induces apoptosis in human ovarian
adenocarcinoma OVCAR3 cells via the regulation of Notch3. Oncol
Rep. 38:1431–1441. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yimlamai D, Christodoulou C, Galli GG,
Yanger K, Pepe-mooney B, Gurung B, Shrestha K, Cahan P, Stanger BZ
and Camargo FD: Hippo pathway activity influences liver cell fate.
Cell. 157:1324–1338. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schilder RJ, Hall L, Monks A, Handel LM,
Fornace AJ Jr, Ozols RF, Fojo AT and Hamilton TC: Metallothionein
gene expression and resistance to cisplatin in human ovarian
cancer. Int J Cancer. 45:416–422. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
van Driel WJ, Lok CA, Verwaal V and Sonke
GS: The role of hyperthermic intraperitoneal intraoperative
chemotherapy in ovarian cancer. Curr Treat Options Oncol.
16:142015.Analgesic and antioxidant activity. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dar A, Faizi S, Naqvi S, Roome T,
Zikr-ur-Rehman S, Ali M, Firdous S and Moin ST: Analgesic and
antioxidant activity of mangiferin and its derivatives: The
structure activity relationship. Biol Pharm Bull. 28:596–600. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ajila CM, Rao LJ and Rao UJ:
Characterization of bioactive compounds from raw and ripe mangifera
indica L. Peel extracts. Food Chem Toxicol. 48:3406–3411. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Duang XY, Wang Q, Zhou XD and Huang DM:
Mangiferin: A possible strategy for periodontal disease to therapy.
Med Hypotheses. 76:486–488. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guha S, Ghosal S and Chattopadhyay U:
Antitumor, immunomodulatory and anti-HIV effect of mangiferin, a
naturally occurring glucosylxanthone. Chemotherapy. 42:443–451.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Iseda S: On Mangiferin, the Coloring
Matter of Mango (Mangifera indica Linn.). V. Identification of
Sugar Component and the Structure of Mangiferin. Bulletin Chem Soc
Japan. 30:629–633. 2006. View Article : Google Scholar
|
|
34
|
Xia Y, Chang T, Wang Y, Liu Y, Li W, Li M
and Fan HY: YAP promotes ovarian cancer cell tumorigenesis and is
indicative of a poor prognosis for ovarian cancer patients. PLoS
One. 9:e917702014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang X, George J, Deb S, Degoutin JL,
Takano EA, Fox SB; AOCS Study group, ; Bowtell DD and Harvey KF:
The Hippo pathway transcriptional co-activator, YAP, is an ovarian
cancer oncogene. Oncogene. 30:2810–2822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hofmann JJ, Zovein AC, Koh H, Radtke F,
Weinmaster G and Iruela-Arispe ML: Jagged1 in the portal vein
mesenchyme regulates intrahepatic bile duct development: Insights
into alagille syndrome. Development. 137:4061–4072. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zong Y, Panikkar A, Xu J, Antoniou A,
Raynaud P, Lemaigre F and Stanger BZ: Notch signaling controls
liver development by regulating biliary differentiation.
Development. 136:1727–1739. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Home P, Saha B, Ray S, Dutta D,
Gunewardena S, Yoo B, Pal A, Vivian JL, Larson M, Petroff M, et al:
Altered subcellular localization of transcription factor TEAD4
regulates first mammalian cell lineage commitment. Proc Natl Acad
Sci USA. 109:7362–7367. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rose SL: Notch signaling pathway in
ovarian cancer. Int J Gynecol Cancer. 19:564–566. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Justice RW, Zilian O, Woods DF, Noll M and
Bryant PJ: The Drosophila tumor suppressor gene warts encodes a
homolog of human myotonic dystrophy kinase and is required for the
control of cell shape and proliferation. Genes Dev. 9:534–546.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pantalacci S, Tapon N and Léopold P: The
salvador partner hippo promotes apoptosis and cell-cycle exit in
drosophila. Nat Cell Biol. 5:921–927. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dong J, Feldmann G, Huang J, Wu S, Zhang
N, Comerford SA, Gayyed MF, Anders RA, Maitra A and Pan D:
Elucidation of a universal size-control mechanism in drosophila and
mammals. Cell. 130:1120–1133. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Overholtzer M, Zhang J, Smolen GA, Muir B,
Li W, Sgroi DC, Deng CX, Brugge JS and Haber DA: Transforming
properties of YAP, a candidate oncogene on the chromosome 11q22
amplicon. Proc Natl Acad Sci USA. 103:12405–12410. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Steinhardt AA, Gayyed MF, Klein AP, Dong
J, Maitra A, Pan D, Montgomery EA and Anders RA: Expression of
Yes-associated protein in common solid tumors. Hum Pathol.
39:1582–1589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zender L, Spector MS, Xue W, Flemming P,
Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, et
al: Identification and validation of oncogenes in liver cancer
using an integrative oncogenomic approach. Cell. 125:1253–1267.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Takeda T, Tsubaki M, Sakamoto K, Ichimura
E, Enomoto A, Suzuki Y, Itoh T, Imano M, Tanabe G, Muraoka O, et
al: Mangiferin, a novel nuclear factor kappa B-inducing kinase
inhibitor, suppresses metastasis and tumor growth in a mouse
metastatic melanoma model. Toxicol Appl Pharmacol. 306:105–112.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ozols RF, Bundy BN, Greer BE, Fowler JM,
Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM
and Baergen R: Gynecologic Oncology Group: Phase III trial of
carboplatin and paclitaxel compared with cisplatin and paclitaxel
in patients with optimally resected stage III ovarian cancer: A
gynecologic oncology group study. J Clin Oncol. 21:3194–3200. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Giaccone G: Clinical perspectives on
platinum resistance. Drugs. 4 Suppl 59:S9–S17. 2000. View Article : Google Scholar
|
|
49
|
Chang Q, Bournazou E, Sansone P, Berishaj
M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, et al:
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and
metastasis. Neoplasia. 15:848–862. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu W, Xie S, Chen X, Rao X, Ren H, Hu B,
Yin T, Xiang Y and Ren J: Activation of the IL-6/JAK/STAT3
signaling pathway in human middle ear cholesteatoma epithelium. Int
J Clin Exp Pathol. 7:709–715. 2014.PubMed/NCBI
|
|
51
|
Wang SW and Sun YM: The IL-6/JAK/STAT3
pathway: Potential therapeutic strategies in treating colorectal
cancer (Review). Int J Oncol. 44:1032–1040. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Taniguchi K, Wu LW, Grivennikov SI, de
Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland BS, Chang JT, et al:
A gp130-Src-YAP module links inflammation to epithelial
regeneration. Nature. 519:57–62. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jeong W, Kim SB, Sohn BH, Park YY, Park
ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DSL, et al:
Activation of YAP1 is associated with poor prognosis and response
to taxanes in ovarian cancer. Anticancer Res. 34:811–817.
2014.PubMed/NCBI
|
